病例报告:在胃肠道筋瘤中,应该将雷戈拉费尼布作为连续治疗方案规定吗? 关于Regorafenib个性化计划的三个案例报告
Maria Susanna Grimaudo1,2, Alice Laffi1, Nicolò Gennaro3
1Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Frontiers in oncology
|June 16, 2023
概括
一个个性化的,连续的Regorafenib计划为转移性胃肠瘤 (GIST) 患者提供了更好的耐受性和症状控制. 这种修改后的饮食方案是标准饮食方案的替代方案,尤其适用于脆弱的个体.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 雷戈拉菲尼布是一种氨酸激酶抑制剂 (TKI),用于转移性GIST,结直肠癌和肝癌.
- 标准的Regorafenib疗程与患者不良的服药性和因毒性而导致的高停药率有关.
- 在科学界中,对个性化Regorafenib剂量计划的需求越来越大.
研究的目的:
- 评估在转移性GIST患者中持续,个性化的Regorafenib管理的可行性和结果.
- 介绍一下肉瘤转诊中心对这种替代治疗方案的经验.
主要方法:
- 追溯收集临床,病理和放射学数据.
- 对三名转移性GIST患者的分析,这些患者每天接受个性化Regorafenib治疗.
- 数据从2021年5月到2022年12月在一个单一的高等推中心收集.
主要成果:
- 三名患者因毒性或症状恶化而转向连续Regorafenib计划.
- 切换后没有报告严重不良事件;与瘤相关的症状有所改善.
- 没有进展的生存率有所不同,其中一名患者在25个月 (连续计划的14个月) 持续生存.
结论:
- 每日个性化的Regorafenib计划显示,在转移性GIST患者中,疗效与降低毒性相匹配.
- 这种疗法对所有转移性GIST患者,包括脆弱的患者来说,是一个潜在的有希望的替代方案.
- 需要进一步的前性研究来验证这种修改后的Regorafenib表的安全性和有效性.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...